CBDMD INC (YCBD)
US12482W3097 - Common Stock
Taking everything into account, YCBD scores 1 out of 10 in our fundamental rating. YCBD was compared to 193 industry peers in the Pharmaceuticals industry. YCBD has a bad profitability rating. Also its financial health evaluation is rather negative. YCBD does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
YCBD had negative earnings in the past year.
In the past year YCBD has reported a negative cash flow from operations.
YCBD had negative earnings in 4 of the past 5 years.
YCBD had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
YCBD's Return On Assets of -169.21% is on the low side compared to the rest of the industry. YCBD is outperformed by 87.43% of its industry peers.
YCBD has a worse Return On Equity (-773.56%) than 82.72% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -169.21% | ||
| ROE | -773.56% | ||
| ROIC | N/A |
ROA(3y)-122.9%
ROA(5y)-82.21%
ROE(3y)-186.47%
ROE(5y)-135.62%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Gross Margin value of 63.43%, YCBD is doing good in the industry, outperforming 69.11% of the companies in the same industry.
YCBD's Gross Margin has declined in the last couple of years.
YCBD does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 63.43% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.51%
GM growth 5Y-4.55%
2. Health
2.1 Basic Checks
YCBD does not have a ROIC to compare to the WACC, probably because it is not profitable.
YCBD has more shares outstanding than it did 1 year ago.
The number of shares outstanding for YCBD has been increased compared to 5 years ago.
Compared to 1 year ago, YCBD has an improved debt to assets ratio.
2.2 Solvency
YCBD has an Altman-Z score of -17.94. This is a bad value and indicates that YCBD is not financially healthy and even has some risk of bankruptcy.
YCBD has a Altman-Z score of -17.94. This is amonst the worse of the industry: YCBD underperforms 84.82% of its industry peers.
YCBD has a Debt/Equity ratio of 0.46. This is a healthy value indicating a solid balance between debt and equity.
YCBD has a Debt to Equity ratio of 0.46. This is in the lower half of the industry: YCBD underperforms 63.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.46 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -17.94 |
ROIC/WACCN/A
WACC9.39%
2.3 Liquidity
A Current Ratio of 0.93 indicates that YCBD may have some problems paying its short term obligations.
YCBD has a Current ratio of 0.93. This is amonst the worse of the industry: YCBD underperforms 87.96% of its industry peers.
A Quick Ratio of 0.52 indicates that YCBD may have some problems paying its short term obligations.
YCBD's Quick ratio of 0.52 is on the low side compared to the rest of the industry. YCBD is outperformed by 95.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.93 | ||
| Quick Ratio | 0.52 |
3. Growth
3.1 Past
YCBD shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -4.73%.
YCBD shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -21.56%.
Measured over the past years, YCBD shows a very strong growth in Revenue. The Revenue has been growing by 120.83% on average per year.
EPS 1Y (TTM)-4.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87.03%
Revenue 1Y (TTM)-21.56%
Revenue growth 3Y-16.76%
Revenue growth 5Y120.83%
Sales Q2Q%-15.46%
3.2 Future
YCBD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 36.40% yearly.
Based on estimates for the next years, YCBD will show a decrease in Revenue. The Revenue will decrease by -6.29% on average per year.
EPS Next Y58.78%
EPS Next 2Y36.4%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-19.71%
Revenue Next 2Y-6.29%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for YCBD. In the last year negative earnings were reported.
Also next year YCBD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as YCBD's earnings are expected to grow with 36.40% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.4%
EPS Next 3YN/A
5. Dividend
5.1 Amount
YCBD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CBDMD INC
NYSEARCA:YCBD (12/18/2024, 11:44:45 AM)
0.37
-0.07 (-15.91%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.65M
Analysts
Price Target
Short Float %
Short Ratio
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -169.21% | ||
| ROE | -773.56% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 63.43% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.46 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.93 | ||
| Quick Ratio | 0.52 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-4.73%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y58.78%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-21.56%
Revenue growth 3Y-16.76%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y